Therapy News and Research

RSS

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Medinox, Inc. in Carlsbad, California and Orient Europharma in Taiwan announce today that they have entered into a partnering agreement to develop and market NOX-100, a new anti-hypotensive drug. Under the terms of the agreement, Orient Europharma holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia. Medinox retains the marketing rights in the United States, Japan and Europe.

12 Apr 2010

Competitive Technologies to introduce Calmare pain therapy at medical conference

Competitive Technologies, Inc. announced today that it will hold a conference for the medical community on May 17, 2010, in Boston, Mass. at the Marriott Long Wharf Hotel from 9:00 a.m. to 3:30 p.m., to introduce CTT's Calmare® pain therapy to the medical community. Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, is the Italian inventor of the "Scrambler Therapy," the technology used in the Calmare medical device.

12 Apr 2010

Results of research study on the expression of KIF6 in mouse model

Celera Corporation and its collaborators at The University of Washington, WA, and Indiana University, IN, today announced the presentation of data from a research study that investigated the expression of KIF6 in a mouse Celera Corporation model. A key finding was that KIF6 was specifically expressed in macrophages and chondrocytes in mouse atherosclerotic lesions, but not in normal arteries.

12 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

Liver biopsy with hepatic copper quantification every 3 years needs to be considered for WD patients

As a result of the rarity of Wilson disease (WD) and the fact that liver biopsy is not performed routinely during follow-up, unless clinically indicated, the progression and timing of the liver pathology and its correlation with different anti-copper treatments or aminotransferase levels are poorly characterized. Previous studies have demonstrated the possibility of improvement of steatosis and inflammation grade, and of fibrosis stage during long-term follow-up.

12 Apr 2010

BeaconEquity.com releases investment report on Cord Blood America

BeaconEquity.com announces an investment report featuring umbilical cord blood stem cell preservation company Cord Blood America. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Apr 2010

High OOP costs discouraging many cancer patients from filling prescriptions

A new study presented today at the Academy of Managed Care Pharmacy's 22nd Annual Meeting finds that one in six cancer patients with high out-of-pocket (OOP) costs abandons their medication. The study by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, found patients with an OOP cost greater than $200 were at least three times more likely to not fill their prescription than those with OOP costs of $100 or less.

12 Apr 2010

Patients receiving medications in 90-day supplies less likely to have adherence problems: Study

A new study presented today at the Academy of Managed Care Pharmacy's 22nd Annual Meeting by Prime Therapeutics, a thought-leader in pharmacy benefit management, provides new evidence to support an easy, low-cost way to help keep patients with chronic conditions on their medications: provide them with a three-month drug supply.

12 Apr 2010

Global study shows wide variations in treatment of women with early breast cancer

A global study of nearly 10,000 women with early breast cancer has found wide variations in how they were treated, despite international consensus on best practice, according to the May issue of the British Journal of Surgery.

12 Apr 2010

Study compares preoperative and postoperative CRT to surgery alone in ESCC patients

Esophagectomy is a standard treatment for resectable esophageal carcinoma but relatively few patients are cured. Combined neoadjuvant chemoradiotherapy (CRT) or adjuvant CRT with surgery may improve survival but there is concern about treatment morbidity and the best sequencing of CRT and surgery.

12 Apr 2010

Internet-based CBT as effective as group therapy for treating panic disorder

Cognitive behaviour therapy (CBT) via the internet is just as effective in treating panic disorder (recurring panic attacks) as traditional group-based CBT. It is also efficacious in the treatment of mild and moderate depression. This according to a new doctoral thesis soon to be presented at the Swedish medical university Karolinska Institutet.

12 Apr 2010

CME program for understanding latest treatment and research on Dupuytren's disease

The Department of Orthopaedics at Stony Brook University Medical Center and the Office of Continuing Medical Education will run a CME program for hand surgeons, hand therapists, rheumatologists, researchers and others interested in understanding the latest treatment and research on Dupuytren's disease, a debilitating hand disorder caused by progressive accumulation of collagen that deforms fingers and limits motion and affects millions worldwide.

12 Apr 2010

Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin

Optimer Pharmaceuticals, Inc. announced that the top-line results from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection were presented today at the 20th Annual European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria.

12 Apr 2010

Researchers find better way to predict treatment outcomes in young leukemia patients

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center may have found a way to more accurately predict treatment outcomes in young leukemia patients using information from a common and simple complete blood count test, also known as a CBC.

12 Apr 2010

FDA issues complete response letter regarding the NDA for OMAPRO

ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.

12 Apr 2010

Patients with end-stage cancer do not benefit from palliative radiotherapy: CANCER

A new analysis has found that a considerable proportion of patients with end-stage or terminal cancer do not benefit from palliative radiation therapy despite spending most of their remaining life undergoing treatments. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that greater efforts are needed to tailor appropriately palliative radiotherapy to patients with end-stage cancer.

12 Apr 2010

Resverlogix highlights features of RVX-208 drug at ATVB conference

Resverlogix Corp. announced today that key scientific data was communicated in an oral presentation highlighting the novel features of RVX-208, the Company's lead drug, during the Atherosclerosis, Thrombosis, Vascular Biology conference being held in San Francisco, California.

12 Apr 2010

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

MaxCyte, Inc., and Medinet Co. Ltd., announced today that they have agreed to amend their License, Development and Supply Agreement for expansion of Medinet's right to use MaxCyte's cell loading technology in Asia Pacific markets.

9 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Secrets to happiness, depression in centenarians identified

Researchers from Iowa State University's gerontology program have helped identify what predicts happiness and long life in centenarians, as well as what causes depression in 80-somethings and above.

9 Apr 2010

Therapy News and Research

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Competitive Technologies to introduce Calmare pain therapy at medical conference

Results of research study on the expression of KIF6 in mouse model

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Liver biopsy with hepatic copper quantification every 3 years needs to be considered for WD patients

BeaconEquity.com releases investment report on Cord Blood America

High OOP costs discouraging many cancer patients from filling prescriptions

Patients receiving medications in 90-day supplies less likely to have adherence problems: Study

Global study shows wide variations in treatment of women with early breast cancer

Study compares preoperative and postoperative CRT to surgery alone in ESCC patients

Internet-based CBT as effective as group therapy for treating panic disorder

CME program for understanding latest treatment and research on Dupuytren's disease

Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin

Researchers find better way to predict treatment outcomes in young leukemia patients

FDA issues complete response letter regarding the NDA for OMAPRO

Patients with end-stage cancer do not benefit from palliative radiotherapy: CANCER

Resverlogix highlights features of RVX-208 drug at ATVB conference

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

Secrets to happiness, depression in centenarians identified

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News